Optic Neuritis – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Optic Neuritis – Pipeline Review, H2 2017’, provides an overview of the Optic Neuritis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Optic Neuritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Optic Neuritis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Optic Neuritis

The report reviews pipeline therapeutics for Optic Neuritis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Optic Neuritis therapeutics and enlists all their major and minor projects

The report assesses Optic Neuritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Optic Neuritis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Optic Neuritis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Optic Neuritis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

2-BBB Medicines BV

Biogen Inc

Bionure Farma SL

Commence Bio Inc

Lipocure Ltd

Meta-IQ ApS

Mitochon Pharmaceuticals Inc

Teijin Pharma Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Optic Neuritis - Overview

Optic Neuritis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Optic Neuritis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Optic Neuritis - Companies Involved in Therapeutics Development

2-BBB Medicines BV

Biogen Inc

Bionure Farma SL

Commence Bio Inc

Lipocure Ltd

Meta-IQ ApS

Mitochon Pharmaceuticals Inc

Teijin Pharma Ltd

Optic Neuritis - Drug Profiles

2B-3201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BN-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CMB-200 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

etomoxir - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gypenoside - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

immune globulin (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

methylprednisolone sodium succinate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MP-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

opicinumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Optic Neuritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-266 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Optic Neuritis - Dormant Projects

Optic Neuritis - Discontinued Products

Optic Neuritis - Product Development Milestones

Featured News & Press Releases

Jan 31, 2017: Noveome Biotherapeutics Publishes Data Demonstrating Anti-inflammatory Activity of ST266 in a Preclinical Model of Optic Neuritis

Oct 01, 2015: Biogen Presents Phase 2 Data On Anti-LINGO-1 at ECTRIMS Congress

Apr 14, 2015: Biogen Presents New Anti-LINGO-1 Phase 2 Acute Optic Neuritis Data Demonstrating Neurological Repair

Jan 08, 2015: Biogen Idec Reports Positive Top-Line Results From Phase 2 Anti-LINGO-1 Trial In People With Acute Optic Neuritis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Optic Neuritis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Optic Neuritis – Pipeline by 2-BBB Medicines BV, H2 2017

Optic Neuritis – Pipeline by Biogen Inc, H2 2017

Optic Neuritis – Pipeline by Bionure Farma SL, H2 2017

Optic Neuritis – Pipeline by Commence Bio Inc, H2 2017

Optic Neuritis – Pipeline by Lipocure Ltd, H2 2017

Optic Neuritis – Pipeline by Meta-IQ ApS, H2 2017

Optic Neuritis – Pipeline by Mitochon Pharmaceuticals Inc, H2 2017

Optic Neuritis – Pipeline by Teijin Pharma Ltd, H2 2017

Optic Neuritis – Dormant Projects, H2 2017

Optic Neuritis – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Optic Neuritis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Targets, H2 2017

Number of Products by Stage and Targets, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports